ym 529 has been researched along with Bone Cancer in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukata, S; Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Shuin, T | 1 |
| Goto, H; Kanematsu, T; Miki, T; Muguruma, H; Sone, S; Uehara, H; Yano, S; Zhang, H | 1 |
| Goto, H; Hanibuchi, M; Miki, T; Sone, S; Uehara, H; Yano, S; Zhang, H | 1 |
| Fukata, S; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Nomura, A; Ohtsuki, Y; Shuin, T | 1 |
| Keller, ET; Miwa, S; Mizokami, A; Namiki, M; Taichman, R; Zhang, J | 1 |
| Kubo, T; Matsuo, T; Ochi, M; Sakai, A; Shimose, S; Tanaka, K; Yasunaga, Y | 1 |
| Kimura, S; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T | 1 |
| Ashimine, S; Hatano, T; Horiguchi, Y; Maeda, H; Ochiai, A; Ogawa, Y; Tachibana, M; Yonou, H; Yoshioka, K | 1 |
| Kubo, T; Matsuo, T; Ochi, M; Sakai, A; Shimose, S | 1 |
| Alcalde, RE; Etoh, Y; Kitamura, K; Matsumura, T; Sasaki, A; Suzuki, A; Tanaka, T | 1 |
10 other study(ies) available for ym 529 and Bone Cancer
| Article | Year |
|---|---|
Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cell Line, Tumor; Diphosphonates; Disease Progression; Humans; Imidazoles; Immunohistochemistry; In Situ Hybridization; In Situ Nick-End Labeling; Interferon-alpha; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Osteoclasts; Xenograft Model Antitumor Assays | 2015 |
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Small Cell; Cell Division; Diphosphonates; Drug Combinations; Etoposide; Humans; Imidazoles; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoclasts; Parathyroid Hormone-Related Protein; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2003 |
Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Topics: Acid Phosphatase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Bone Resorption; Carcinoma, Transitional Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Proliferating Cell Nuclear Antigen; Tartrate-Resistant Acid Phosphatase; Taxoids; Tibia; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2005 |
The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Topics: Animals; Bone Marrow; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chemokine CXCL12; Chemokines, CXC; Diphosphonates; Humans; Imidazoles; Male; Mice; Mice, SCID; Neoplasm Invasiveness; Osteoblasts; Prostatic Neoplasms; Receptors, CXCR4; Xenograft Model Antitumor Assays | 2005 |
Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imidazoles; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Sarcoma; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Cisplatin; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Paclitaxel; Protein Prenylation; rap1 GTP-Binding Proteins; ras Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Topics: Animals; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Osteoblasts; Prostatic Neoplasms; Transplantation, Heterologous | 2007 |
Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Topics: Animals; Antibiotics, Antineoplastic; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Doxorubicin; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; GTP-Binding Proteins; Humans; Imidazoles; Indicators and Reagents; Mice; Mice, Nude; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Protein Prenylation; Sarcoma, Ewing; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Imidazoles; Mice; Mice, Nude; Neoplasm Transplantation; Osteolysis | 1998 |